The Series B round, led by Altos Ventures with participation from existing investors, will accelerate Amae’s AI-powered precision-care platform and partnerships with leading academic medical centers—marking a decisive step toward curative psychiatry

More than 15 million Americans live with severe mental illness (SMI) and remain stuck in a cycle of crisis care. Amae Health, a Public Benefit Corporation (PBC) and leader in outpatient treatment for SMI, today announced a $25 million pre-empted Series B financing, bringing total funding to more than $50 million, to transform how these conditions are understood, treated, and ultimately cured. The round was led by Altos Ventures with participation from all existing investors, including Quiet Capital, Bling Capital, Cedars-Sinai Ventures, Healthier Capital, and 8VC.

The new funding will accelerate the opening of Amae clinics nationwide, advance its proprietary AI-driven care platform, and support research into schizophrenia, bipolar disorder, and treatment-resistant depression. It will also strengthen partnerships with leading academic medical centers to expand access to Amae’s integrated model of care.

“Severe mental illness devastates families and communities, yet traditional treatment models haven’t moved the needle,” said Stas Sokolin, Co-Founder and CEO of Amae Health. “We’re taking a different path; combining compassionate, in-person care with responsibly deployed AI that helps clinicians determine the best course for each individual. Our north star is a true cure, defined as it is in oncology: five or more years of remission.”

Expanding In-Person SMI Care Across the Country

Since opening its first clinic in Los Angeles in 2022, Amae has partnered with leading health systems including NewYork-Presbyterian, Cedars-Sinai and Stanford Health Care to bring high-quality, team-based outpatient care to communities in need. Clinics staffed by psychiatrists, therapists, primary care providers, dietitians, and social services specialists deliver coordinated treatment tailored to each patient.

Unlike virtual-only or chatbot-driven models, Amae combines face-to-face care with advanced technology that truly supports and empowers our clinicians. This approach has achieved striking results:

• Reduced 30-day hospital readmissions to <4%, compared to a 23% national average
• Attained measurement-based care score improvements of 76% in mania, 61% in psychosis, and 49% in suicidality
• Delivered 100% 7-day and 30-day post-hospitalization follow-up through Amae’s same-day intake model
• Achieved a Net Promoter Score (NPS) of 90, reflecting exceptional patient experience

“Amae is advancing a model of care that prioritizes clinical excellence and compassionate, patient-centered services,” said Dr. Itai Danovitch, Chair of the Department of Psychiatry and Behavioral Neurosciences at Cedars-Sinai Medical Center. “By combining an outstanding team of clinicians with a thoughtful approach to long-term care, Amae is delivering outcomes that are both significant and sustainable.”

Responsible AI Features that Enhance Patient Care

Amae’s precision medicine platform is built on Palantir Foundry and integrates data from wearables, measurement-based assessments, and patient records. This system enables providers to identify patterns, track treatment response, and coordinate across the full care team.

Three new features are reshaping how clinicians care for patients:

• Patient-at-a-Glance: A unified dashboard that synthesizes inputs from clinical assessments, wearables, and health records to give providers a clear, longitudinal view of each patient’s progress.
• Point of Care Assistant: An AI-powered clinical assistant that monitors patient status, flags meaningful changes, and offers treatment recommendations. Providers remain fully in control, approving or adjusting each suggestion with their judgment.
• Symptomology Phenotyping: Symptom clustering based on longitudinal patient data allows for the creation of digital phenotypes. Providers can use these phenotypes to deliver highly effective, precise care based on a patient’s unique set of symptoms.

These features have allowed Amae to set a new standard for SMI care, one that pairs the scalability of AI with the deep precision, and humanity of in-person treatment. Deployed alongside leading health systems across the country, this model has the potential to fundamentally reshape how SMI is treated, and ultimately, how it’s cured.

The Amae Institute: Accelerating the Path to Cures

To further its mission, Amae has established the Amae Institute, a center for excellence dedicated to advancing care for SMI. The Amae Institute partners with leading research hospitals and academic experts to develop next-generation treatments and accelerate the scientific progress needed to achieve long-term remission and, ultimately, a cure.

Learn more at https://www.amaehealth.com/amae-institute

About Amae Health

Amae Health is dedicated to helping the 15.4 million Americans living with severe mental illness (SMI) lead stable, fulfilling lives – and ending the cycle of repeat hospitalizations. Partnering with top health systems nationwide, Amae delivers a groundbreaking outpatient model that combines compassionate, in-person psychiatric care with wraparound support and AI-powered clinical tools. By treating physical, mental, and social needs together, Amae enables its members to not just survive, but thrive.

Learn more at www.amaehealth.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20251105989926/en/

Our north star is a true cure, defined as it is in oncology: five or more years of remission. — Stas Sokolin, Co-Founder and CEO of Amae Health